Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC2 | Q92769 | 1/20 | 0.67 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.67 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.67 |
| ▸ | HPGD | P15428 | 3/20 | 0.61 |
| ▸ | HTT | P42858 | 2/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | MPO | P05164 | 1/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | KDM5A | P29375 | 1/20 | 0.60 |
| ▸ | BLM | P54132 | 1/20 | 0.60 |
| ▸ | GFER | P55789 | 1/20 | 0.60 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.60 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.60 |
| ▸ | PLK1 | P53350 | 7/20 | 0.59 |
| ▸ | CA2 | P00918 | 2/20 | 0.55 |
| ▸ | CA12 | O43570 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 1/20 | 0.54 |
| ▸ | CA7 | P43166 | 1/20 | 0.54 |
| ▸ | CA9 | Q16790 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14676072 | 0.93 | HDAC2 (0.59) | HDAC2HDAC8HDAC6HPGDHTT | |
| SCHEMBL250247 | 0.89 | HDAC6 (0.80) | HDAC2HDAC8HDAC6HPGDHTT | |
| SCHEMBL16610200 | 0.88 | DEGS1 (0.64) | HDAC2HDAC8HDAC6TSHRSMN1; SMN2 | |
| SCHEMBL6388803 | 0.88 | HPGD (0.85) | HDAC2HDAC8HDAC6HPGDHTT | |
| SCHEMBL29202850 | 0.84 | GFER (0.65) | HPGDHTTSMN1; SMN2MPOCYP3A4 | |
| SCHEMBL14266881 | 0.83 | GFER (0.58) | HDAC2HDAC8HDAC6HPGDHTT | |
| SCHEMBL14115137 | 0.82 | HDAC6 (0.70) | HDAC2HDAC8HDAC6HPGDHTT | |
| SCHEMBL16198923 | 0.82 | HDAC6 (0.70) | HDAC2HDAC8HDAC6HPGDHTT | |
| SCHEMBL7537701 | 0.81 | CYP3A4 (0.56) | HPGDHTTTSHRSMN1; SMN2MPO | |
| SCHEMBL25193972 | 0.80 | F3 (0.74) | CYP3A4MAPTALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 203 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101553493-A | Novel tricyclic spiropiperidine compounds, their synthesis and their use as modulators of chemokine receptor activity | ASTRAZENECA AB (SE) | 2009-10-07 | — | — | CN | claimed |
| EP-0469742-B1 | Production of acetaminophen | HOECHST CELANESE CORP (US) | 1997-01-22 | — | — | EP | claimed |
| US-5155273-A | Adding Beckmann rearrangement catalyst having electrophilic carbon atom to 4-hydroxyacetophenone oxime | HOECHST CELANESE CORPORATION (US) | 1992-10-13 | — | — | US | claimed |
| EP-0469742-A2 | Production of acetaminophen | HOECHST CELANESE CORPORATION (US) | 1992-02-05 | — | — | EP | claimed |
| EP-4709384-A2 | COMBINATION THERAPY FOR TREATMENT OF CANCER | PMV Pharmaceuticals, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| EP-4598933-A1 | PHOSPHORAMIDATE COMPOUNDS AND USES THEREOF | Allorion Therapeutics Inc (US) | 2025-08-13 | — | — | EP | disclosed |
| CN-119968377-A | Phosphoramidate compounds and uses thereof | 安锐生物医药公司 | 2025-05-09 | — | — | CN | disclosed |
| WO-2024238404-A2 | COMBINATION THERAPY FOR TREATMENT OF CANCER | PMV PHARMACEUTICALS, INC. (US) | 2024-11-21 | — | — | WO | disclosed |
| CN-118206529-A | Dihydrobenzimidazolone | C4医药公司 | 2024-06-18 | — | — | CN | disclosed |
| WO-2024078392-A1 | PHOSPHORAMIDATE COMPOUNDS AND USES THEREOF | ANRUI BIOMEDICAL TECHNOLOGY (GUANGZHOU) CO., LTD. (CN) | 2024-04-18 | — | — | WO | disclosed |
| US-20240109889-A1 | DIHYDROBENZIMIDAZOLONES FOR MEDICAL TREATMENT | C4 THERAPEUTICS, INC. (US) | 2024-04-04 | — | — | US | disclosed |
| CN-111315735-B | Dihydrobenzimidazolone | C4医药公司 | 2024-03-08 | — | — | CN | disclosed |
| US-5248758-A | Curable composition | THE DOW CHEMICAL COMPANY (US) | 1993-09-28 | — | — | US | disclosed |
| US-5248757-A | Curable composition | THE DOW CHEMICAL COMPANY (US) | 1993-09-28 | — | — | US | disclosed |
| US-5206321-A | Polycyanates containing mesogenic moieties as lateral substituents | THE DOW CHEMICAL COMPANY (US) | 1993-04-27 | — | — | US | disclosed |
| US-5155273-A | Adding Beckmann rearrangement catalyst having electrophilic carbon atom to 4-hydroxyacetophenone oxime | HOECHST CELANESE CORPORATION (US) | 1992-10-13 | — | — | US | disclosed |
| EP-0469742-A2 | Production of acetaminophen | HOECHST CELANESE CORPORATION (US) | 1992-02-05 | — | — | EP | disclosed |
| US-5077380-A | Mesogenic cyanate functional maleimides and thermosets thereof | THE DOW CHEMICAL COMPANY (US) | 1991-12-31 | — | — | US | disclosed |
| EP-0409069-A2 | Mesogenic polycyanates and thermosets thereof | THE DOW CHEMICAL COMPANY (US) | 1991-01-23 | — | — | EP | disclosed |
| EP-0409070-A2 | Mesogenic cyanite functional maleimides and thermosets thereof | THE DOW CHEMICAL COMPANY (US) | 1991-01-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240109889-A1 | DIHYDROBENZIMIDAZOLONES FOR MEDICAL TREATMENT | CRBN, CUL4A, ADRM1 | HDAC2 1597/4885HDAC8 1168/4885HDAC6 1031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.